期刊
PATHOGENS
卷 12, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/pathogens12060841
关键词
intravenous fosfomycin; urinary tract infection; efficacy; nephrotoxicity
类别
This retrospective study evaluated the use and side effects of fosfomycin in critically ill patients in Taiwan. The study included 42 patients who received fosfomycin treatment from a teaching hospital. The main indication for fosfomycin use was urinary tract infections, with Escherichia coli being the most frequently identified pathogen. The study found that fosfomycin combined with other drugs had a high clinical success rate and may be an effective and safe antibiotic for multidrug-resistant infections in critically ill patients.
This retrospective study aimed to evaluate the clinical use and side effects of fosfomycin in critically ill patients in Taiwan. Forty-two patients (mean age, 69.9 years; female, 69%) who received fosfomycin were included from a teaching hospital in Taiwan from January 2021 to December 2021. We analyzed the prescription pattern of intravenous fosfomycin and evaluated patient safety profiles, clinical successes, and microbiological cure rates. The main indication was urinary tract infections (35.6%), and the most frequently identified pathogen was Escherichia coli (18.2%). The overall clinical success was 83.4%, with one multidrug-resistant pathogen isolated from eight patients (19.0%). The average dose of fosfomycin given was 11.1 & PLUSMN; 5.2 g/day. The average duration of therapy was 8.7 & PLUSMN; 5.9 days, with a median duration of 8 days, where fosfomycin was mostly (83.3%) given in combination. Fosfomycin was given 12 hourly to a maximum number (47.6%) of cases. The incidence rates of adverse drug reactions (hypernatremia and hypokalemia) were 33.33% (14/42) and 28.57% (12/42), respectively. The overall survival rate was 73.8%. Intravenous fosfomycin may be an effective and safe antibiotic to use in combination with other drugs for empirical broad-spectrum or highly suspected multidrug-resistant infections in critically ill patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据